Cargando…

Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1

BACKGROUND: The aim of this retrospective study was to define clinical and molecular characteristics of a large sample of neurofibromatosis type 1 (NF1) patients, as well as to evaluate mutational spectrum and genotype-phenotype correlation. NF1 is a relatively common neurogenetic disorder (1:2500–1...

Descripción completa

Detalles Bibliográficos
Autores principales: Corsello, Giovanni, Antona, Vincenzo, Serra, Gregorio, Zara, Federico, Giambrone, Clara, Lagalla, Luca, Piccione, Maria, Piro, Ettore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885309/
https://www.ncbi.nlm.nih.gov/pubmed/29618358
http://dx.doi.org/10.1186/s13052-018-0483-z
_version_ 1783311958362030080
author Corsello, Giovanni
Antona, Vincenzo
Serra, Gregorio
Zara, Federico
Giambrone, Clara
Lagalla, Luca
Piccione, Maria
Piro, Ettore
author_facet Corsello, Giovanni
Antona, Vincenzo
Serra, Gregorio
Zara, Federico
Giambrone, Clara
Lagalla, Luca
Piccione, Maria
Piro, Ettore
author_sort Corsello, Giovanni
collection PubMed
description BACKGROUND: The aim of this retrospective study was to define clinical and molecular characteristics of a large sample of neurofibromatosis type 1 (NF1) patients, as well as to evaluate mutational spectrum and genotype-phenotype correlation. NF1 is a relatively common neurogenetic disorder (1:2500–1:3000 individuals). It is caused by mutations of the NF1 gene on chromosome 17ql1.2, with autosomal dominant pattern of inheritance and wide phenotypical variability. Café-au-lait spots (CALs), cutaneous and/or subcutaneous neurofibromas (CNFs/SCNFs), skinfold freckling, skeletal abnormalities, Lisch nodules of the iris and increased risk of learning and intellectual disabilities, as well as tumors of the nervous system and other organs are its main clinical features. METHODS: The preliminary group collected 168 subjects with clinical suspicion of NF1. They were evaluated following the National Institutes of Health (NIH) criteria for NF1, revised by Gutmann et al. 1997, integrated for 67 of them by molecular testing. According to these references, 112 of 168 patients were diagnosed as NF1. The sample was characterized by an equal sex ratio (57 males, 55 females) and age distribution ranging from 10 days to 60 years of age (mean age, 13 years). RESULTS: A wide spectrum of clinical features has been observed in our patients. Mutational analysis resulted positive in 51 cases (76%). Twenty-four mutations detected in our cohort have not been reported to date. CONCLUSIONS: This study may contribute to a better definition of genotypic and phenotypic features of NF1 patients, with respect to further insights into the clinical characterization of the disease. In addition, an amplification of the spectrum of mutations in the NF1 gene has been documented.
format Online
Article
Text
id pubmed-5885309
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58853092018-04-09 Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1 Corsello, Giovanni Antona, Vincenzo Serra, Gregorio Zara, Federico Giambrone, Clara Lagalla, Luca Piccione, Maria Piro, Ettore Ital J Pediatr Research BACKGROUND: The aim of this retrospective study was to define clinical and molecular characteristics of a large sample of neurofibromatosis type 1 (NF1) patients, as well as to evaluate mutational spectrum and genotype-phenotype correlation. NF1 is a relatively common neurogenetic disorder (1:2500–1:3000 individuals). It is caused by mutations of the NF1 gene on chromosome 17ql1.2, with autosomal dominant pattern of inheritance and wide phenotypical variability. Café-au-lait spots (CALs), cutaneous and/or subcutaneous neurofibromas (CNFs/SCNFs), skinfold freckling, skeletal abnormalities, Lisch nodules of the iris and increased risk of learning and intellectual disabilities, as well as tumors of the nervous system and other organs are its main clinical features. METHODS: The preliminary group collected 168 subjects with clinical suspicion of NF1. They were evaluated following the National Institutes of Health (NIH) criteria for NF1, revised by Gutmann et al. 1997, integrated for 67 of them by molecular testing. According to these references, 112 of 168 patients were diagnosed as NF1. The sample was characterized by an equal sex ratio (57 males, 55 females) and age distribution ranging from 10 days to 60 years of age (mean age, 13 years). RESULTS: A wide spectrum of clinical features has been observed in our patients. Mutational analysis resulted positive in 51 cases (76%). Twenty-four mutations detected in our cohort have not been reported to date. CONCLUSIONS: This study may contribute to a better definition of genotypic and phenotypic features of NF1 patients, with respect to further insights into the clinical characterization of the disease. In addition, an amplification of the spectrum of mutations in the NF1 gene has been documented. BioMed Central 2018-04-04 /pmc/articles/PMC5885309/ /pubmed/29618358 http://dx.doi.org/10.1186/s13052-018-0483-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Corsello, Giovanni
Antona, Vincenzo
Serra, Gregorio
Zara, Federico
Giambrone, Clara
Lagalla, Luca
Piccione, Maria
Piro, Ettore
Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
title Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
title_full Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
title_fullStr Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
title_full_unstemmed Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
title_short Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1
title_sort clinical and molecular characterization of 112 single-center patients with neurofibromatosis type 1
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885309/
https://www.ncbi.nlm.nih.gov/pubmed/29618358
http://dx.doi.org/10.1186/s13052-018-0483-z
work_keys_str_mv AT corsellogiovanni clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT antonavincenzo clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT serragregorio clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT zarafederico clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT giambroneclara clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT lagallaluca clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT piccionemaria clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1
AT piroettore clinicalandmolecularcharacterizationof112singlecenterpatientswithneurofibromatosistype1